Response to fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: Better 5-year survival or artefactual result of research methodology?

摘要

We are grateful for the opportunity to reply to Dr Njei's letter, which raised the question of whether a better 5-year survival for patients with fibrolamellar hepatocellular carcinoma (fHCC) versus patients with hepatocellular carcinoma (HCC) (that we recently reported), was real or an artefact of research methodology.1 In the letter, results of a meta-analysis were presented which were interpreted to show that the survival of fHCC and HCC do not differ in non-cirrhotic patients. We disagree with this interpretation of the results.